

Table S1. Checklist for risk of bias assessment and explanations

| Study | Domain of assessment | Criteria | Risk of bias | Explanation |
|-------|--|--------------------------------|--------------|---|
| | Number of participants and MgSO₄ sampling | ≥10 or dense sampling in ≥5 | Low | ≥10 women treated with MgSO ₄ for preeclampsia and/or eclampsia with serum magnesium concentration measured against time OR ≥5 women with dense sampling per subject. |
| | | <10 or sparse sampling in ≥5-9 | High | <10 women treated with MgSO ₄ for preeclampsia and/or eclampsia with serum magnesium concentration measured against time OR <5 women with dense sampling per subject. |
| | | Unclear | Unclear | Number of participants with serum magnesium estimation was not reported. |
| | Was the spectrum of patients clearly representative of the patients who will receive the test in practice? | Yes | Low | The study used criteria that are accepted to define preeclampsia or eclampsia or made reference to the criteria. |
| | | No | High | The study did not use criteria that are accepted to define preeclampsia or eclampsia or make reference to the criteria. |
| | | Unsure | Unclear | Study reported use of MgSO ₄ for women with “toxaemia”, “preeclampsia” and / or “eclampsia” without any reference to clear criteria for selecting study participants. |
| | Did the study report on important covariates (e.g. demographic characteristics - maternal age, gestation age, race, | Yes | Low | Details of relevant covariates were provided in the report for all women or as a range. |
| | | No | High | No report of relevant covariates provided in the report. |
| | | Unclear | Unclear | Covariate sparsely reported for women or described as arithmetic mean or |

body weight or body mass index)?

percentages.

| | | | |
|--|-----------------------|---------|--|
| Extent to which study objective align with the systematic review objective | Yes | Low | The primary objective of the study was to assess serum level magnesium concentrations or pharmacokinetic properties of MgSO ₄ in women with preeclampsia and/ or eclampsia. It covers Absorption, Distribution, Metabolism, Excretion (ADME). |
| | No | High | The primary objective of the study was not to assess serum magnesium level or pharmacokinetic properties of MgSO ₄ in preeclampsia and/or eclampsia but serum Mg concentration was assessed as part of the study components. |
| | Uncertain | Unclear | The study objective was not clearly reported and does not fall into any of the above categories. |
| Was laboratory method used to estimate serum magnesium described in detail? | Yes | Low | Sample collection explained including storage conditions of samples prior to estimation of serum magnesium. The equipment, model, manufacturer and peculiarities of laboratory method described. |
| | No | High | No description of method of serum magnesium estimation. |
| | Unclear | Unclear | Partial description of the storage conditions of samples prior to estimation of serum magnesium, the equipment, model, manufacturer and or the peculiarities of laboratory method. |
| Is the technology of test unchanged since the study was carried out | No | Low | Method and equipment used to estimate serum magnesium concentration have not changed since study was conducted. |
| | Yes | High | Method and equipment used to estimate serum magnesium have changed since study was conducted. |
| | Unsure | Unclear | Unable to ascertain if technique and equipment used to estimate serum magnesium have not changed since study was conducted |
| Baseline reporting and | Baseline reported and | Low | Baseline and post-dose serial serum magnesium concentration reported against time for up to 24 hours (i.e. sampling covers absorption phase, |

| | | | |
|--|---|---------|---|
| duration of post-dose estimation of serum magnesium | post-dose estimation ≥ 24 hours | | maximum concentration region and elimination phase). |
| | No baseline reported or post-dose estimation < 24 hours | High | Baseline not reported or post-dose serial serum magnesium concentration reported against time for less than 24 hours (i.e. sampling does not cover absorption phase, maximum concentration region and elimination phase). |
| | Unreported or unclear reporting | Unclear | Baseline serum magnesium was not reported and post-dose serial measurement was not performed up to 24 hours OR baseline serum magnesium was reported but post-dose serial measurement was not performed up to 24 hours. |
| Were withdrawals from the study explained | Yes/ No withdrawals | Low | Less than 20% withdrawal or explanation suggests that withdrawals would not bias the study findings |
| | No | High | More than 20% withdrawal or explanation suggests that withdrawals would bias the study findings. |
| | Unclear | Unclear | No explanation provided for withdrawals. |
